Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tiziana Life Sciences Ltd (NQ: TLSA )

0.7800 +0.1067 (+15.85%)
Streaming Delayed Price Updated: 11:01 AM EDT, Mar 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 91,494
Open 0.6970
Bid (Size) 0.7700 (4)
Ask (Size) 0.7900 (7)
Prev. Close 0.6733
Today's Range 0.6962 - 0.7800
52wk Range 0.5005 - 1.380
Shares Outstanding 194,612,289
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
From Tiziana Life Sciences Ltd.
Via Globe NewsWire
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
From Tiziana Life Sciences Ltd.
Via Globe NewsWire

Performance

YTD
+34.48%
+34.48%
1 Month
+34.48%
+34.48%
3 Month
+31.18%
+31.18%
6 Month
+13.67%
+13.67%
1 Year
-34.45%
-34.45%

More News

Read More
Tiziana Life Sciences Highlighted in Forbes Article
From Tiziana Life Sciences Ltd.
Via Globe NewsWire
Tiziana Life Sciences Announces Publication in Proceedings of the National Academy of Sciences (PNAS) Illustrating the Immunological Basis of the Mechanism of Action for Intranasal Foralumab
From Tiziana Life Sciences Ltd.
Via Globe NewsWire
7 Thrilling Stocks to Buy for Aggressive Investors
Via InvestorPlace
Proactive research analyst says Tiziana Life Sciences "moving forward quite nicely"
Via News Direct
Proactive research analyst says Tiziana Life Sciences "moving forward quite nicely"
Via TheNewswire.com
Tesla HODLs Bitcoin — But Sticks To Dogecoin-Only Crypto Payments Policy
Via Benzinga
Tiziana Life Sciences Announces IND filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung Cancer
From Tiziana Life Sciences Ltd.
Via Globe NewsWire
Tiziana Life Sciences Posts Additional Clinical Improvements In Second Patient with Multiple Sclerosis
Via Benzinga
Tiziana Life Sciences Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) After Eleven Months of Dosing with Intranasal Foralumab
From Tiziana Life Sciences Ltd.
Via Globe NewsWire
Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Updated Interim Results for the Six Months Ended 30 June 2022
From Tiziana Life Sciences Ltd.
Via Globe NewsWire
Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Interim Results for the Six Months Ended 30 June 2022
From Tiziana Life Sciences Ltd.
Via Globe NewsWire
Tiziana to Participate in January Investor Meetings
From Tiziana Life Sciences Ltd.
Via Globe NewsWire
Tiziana Life Sciences Announces Completion of Prerequisite Pre-Clinical Safety Study
From Tiziana Life Sciences Ltd.
Via Globe NewsWire
Tiziana Life Sciences Ltd. Granted 180-day Extension by Nasdaq to Meet Minimum Bid Price Requirements
From Tiziana Life Sciences Ltd.
Via Globe NewsWire
Tiziana Life Sciences Announces Date of Annual General Meeting 2022
From Tiziana Life Sciences Ltd.
Via Globe NewsWire
Tiziana Announces Publication of a Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T cell Function and an Induced T Cell Regulatory Response in Human Subjects
From Tiziana Life Sciences Ltd.
Via Globe NewsWire
Tiziana Life Sciences Announces Near-Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (CNS)
From Tiziana Life Sciences Ltd.
Via Globe NewsWire
Tiziana Life Sciences to Host Investor Call
From Tiziana Life Sciences Ltd.
Via Globe NewsWire
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
From Tiziana Life Sciences Ltd.
Via Globe NewsWire
Tiziana Life Sciences Completes Enrollment of the First Patient Cohort for its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients
From Tiziana Life Sciences Ltd.
Via Globe NewsWire
Tiziana Life Sciences Starts Enrollment of the First Patient Cohort in its Intermediate Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients
From Tiziana Life Sciences Ltd.
Via Globe NewsWire
Tiziana Life Sciences Ltd Invites You to Join Us at The ThinkEquity Conference
From Tiziana Life Sciences Ltd.
Via Globe NewsWire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.